July 1, 1985

Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Sequential high-dose cytosine arabinoside (ara-C) and asparaginase were given to 41 children age six months to 21 years of age with advanced leukemia. Ten of 22 patients with acute lymphocytic leukemia (ALL) and eight of 19 patients with acute nonlymphocytic leukemia (ANLL) obtained complete remissions. The most significant toxicity seen was infection in 22 patients. In addition, patients given intrathecal chemotherapy within 24 hours of ara-C developed neurologic toxicity. The high response rate seen in these patients with advanced leukemia indicates that a trial of this regimen is warranted in children with less advanced ALL and ANLL.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Wells et al. (Mon,) studied this question.

synapsesocial.com/papers/6a225c89eec6361cd1b602bb https://doi.org/https://doi.org/10.1200/jco.1985.3.7.998

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar